Savior Lifetec Corporation engages in the research, development, design, manufacture, and sale of carbapenem generics in the Americas, Asia, Taiwan, Europe, and internationally. The company offers injection generics, controlled-release generics, the development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms. It also provides medicine manufacturer technology and services. In addition, the company sells antibacterial raw materials and injectables. Savior Lifetec Corporation was founded in 1993 and is headquartered in Tainan City, Taiwan.
Frequently asked questions
What sector does Savior Lifetec (4167) operate in?
Savior Lifetec belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Savior Lifetec (4167) current stock price?
As of the latest data, Savior Lifetec stock price is NT$19.15, with a previous close of NT$18.35. Savior Lifetec gained NT$0.80 in the last trading session, representing a 4.36% increase.
What is Savior Lifetec (4167) current market capitalization?
Savior Lifetec market cap is approximately 6.35 billion.
What is Savior Lifetec (4167) Earnings Per Share (EPS)?
The trailing EPS is NT$0.74.
What is Savior Lifetec (4167) Price-to-Earnings (P/E) ratio?
Savior Lifetec current P/E ratio is 25.88.
Does Savior Lifetec (4167) pay dividends?
Yes. Savior Lifetec pays annual dividends with an annualized yield of 4.2% and an estimated annual payout of NT$0.80 per share.
When is the next ex-dividend date for Savior Lifetec (4167)?
The next ex-dividend date is scheduled for July 28, 2027.
What is Savior Lifetec (4167) beta (volatility) score?
Savior Lifetec has a beta of 0.105, indicating lower volatility than the overall market.
